1. New updates in the world of hepatitis C virus infected organ transplantation.
- Author
-
Prakash K and Aslam S
- Subjects
- Antiviral Agents therapeutic use, Hepacivirus drug effects, Hepatitis C drug therapy, Hepatitis C epidemiology, Hepatitis C virology, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Humans, Tissue and Organ Procurement methods, Viremia drug therapy, Viremia epidemiology, Viremia virology, Hepacivirus isolation & purification, Hepatitis C, Chronic epidemiology, Living Donors statistics & numerical data, Organ Transplantation methods, Organ Transplantation statistics & numerical data
- Abstract
Purpose of Review: With the advent of direct acting antiviral (DAA) therapy, the use of organs from hepatitis C virus infected (HCV+) donors is gaining more traction. In this review, we aim to: provide an overview of recent literature that supports the use of HCV+ organs, outline ongoing challenges to the use of these organs, and highlight the areas within this field where active investigation is ongoing., Recent Findings: The present review describes clinical outcomes related to the transplantation of both HCV+ nonviremic and viremic organs and the distinction between hepatic and nonhepatic transplants. It also discusses the current debate pertaining to the ideal treatment strategy for donor-derived HCV infection, that is pre-emptive therapy versus prophylaxis therapy., Summary: Data suggest that the use of HCV+ organs is an effective and relatively well tolerated strategy to combat the organ scarcity. However, clinicians must be vigilant to a signal of increased inflammation as HCV+ organ transplantation becomes more universal. Recent studies suggest that shorter courses of DAA may sufficiently treat donor-derived HCV infection, however the best treatment approach to minimize risk, cost, and toxicity is still under investigation.
- Published
- 2020
- Full Text
- View/download PDF